Gamida Cell Stock News

Why are these penny stocks moving in the stock market today? The post 5 Hot Penny Stocks To Watch With Premarket Momentum & News appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q4 2021 Results - Earnings Call Transcript

Gamida Cell (NASDAQ: GMDA ) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Gamida Cell beat estimated earnings by 15.0%, reporting … Full story available on Benzinga.com

Gamida Cell press release (GMDA): FY GAAP EPS of -$1.52 misses by $0.10. As of December 31, 2021, the company had total cash and cash equivalents of $95.9M.Shares -4.19% PM.

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided a business update and reported financial results for the year and quarter ended December 31, 2021. Net loss for 2021 was $89.8 million, compared to a net loss of $61.6 million in 2020. As of December 31, 2021, Gamida Cell had total cash and cash equivalents of $95.9 million. During the past quarter and into 2022, Gamida Cell: Continu

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ: IDYA ) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi Trends (NASDAQ: CTRN ) is projected to report quarterly earnings at $1.12 per share on revenue of $250.54 million. • Precision BioSciences (NASDAQ: DTIL ) is likely to report quarterly loss at $0.47 per share on revenue of $7.75 million. • SPX FLOW (NYSE: FLOW ) is estimated to report quarterly loss at $0.17 per share on revenue of $10.88 million. • Brickell Biotech (NASDAQ: BBI ) is likely to report quarterly loss at $0.08 per share on revenue of $150.00 thousand. • Imara (NASDAQ: IMRA ) is expected to report earnings for its fourth quarter. • Gamida Cell (NASDAQ: GMDA ) is estimated to report earnings for its fourth quarter. • Syros Pharmaceuticals (NASDAQ: SYRS ) is likely to report quarterly loss at $0.47 per share on revenue of $4.80 million. • Global X Guru Index ETF (NYSE: GURU ) is likely to report quarterly loss at $0.

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the upcoming Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 2:00 p.m. ET. The webcast will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days followi

Gamida (GMDA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Shares of Gamida Cell have surged higher after the company today said it started a rolling submission of a Biologics License Application for omidubicel.

Gamida Cell Ltd (NASDAQ: GMDA ) … Full story available on Benzinga.com

Gamida Cell (GMDA) began a rolling submission of its biologics license application ((BLA)) with the U.S

Gamida Cell Ltd GMDA has initiated the Biologics License Application (BLA) rolling submission process with the FDA for omidubicel, in patients with blood cancers needing stem cell transplant.  Get

Gamida Cell (GMDA) announces key program and business updates.Following the recent receipt of positive Type B meeting correspondence from the FDA, the company will initiate a rolling

Gamida Cell Ltd GMDA will terminate 10% of its staff as part of an effort to extend its cash runway for a planned filing for cell therapy omidubicel with the FDA. [ALERT] Nic Chahine shares his Bea